Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically documented adenocarcinoma of the prostate~* Progressive, systemic (metastatic) disease despite castrate levels of testosterone due to orchiectomy or luteinizing-hormone releasing hormone (LHRH) agonist, meeting 1 of the following criteria:~  * Measurable disease, defined as any lesion that can be accurately measured in at least 1 dimension ≥ 2 cm by conventional techniques or ≥ 1 cm by spiral CT scan or MRI~ * Nonmeasurable disease with PSA ≥ 5 ng/mL~    * Bone lesions~   * Pleural or pericardial effusions, ascites~   * CNS lesions, leptomeningeal disease~   * Irradiated lesions, unless progression documented after radiotherapy~   * No PSA ≥ 5 ng/mL as only evidence of disease~ * PSA evidence for progressive prostate cancer consists of a PSA level ≥ 5 ng/mL that has risen on ≥ 2 successive occasions, ≥ 2 weeks apart~* Castrate levels of testosterone (\< 50 ng/dL) must be maintained~  * If no prior orchiectomy, patients must remain on testicular androgen suppression (e.g., with an LHRH analogue)~* Patients receiving an antiandrogen as part of primary androgen ablation must demonstrate disease progression after discontinuation of antiandrogen~  * Disease progression after antiandrogen withdrawal is defined as 2 consecutive rising PSA values, obtained at least 2 weeks apart, or documented osseous or soft tissue progression~    * For patients receiving flutamide or megestrol acetate, at least 1 of the PSA values must be obtained 4 weeks or more after flutamide/megestrol acetate discontinuation~   * For patients receiving bicalutamide or nilutamide, at least 1 of the PSA values must be obtained 6 weeks or more after antiandrogen discontinuation~ * If improvement after antiandrogen withdrawal is noted, disease progression must be established~* No pleural effusion or ascites that causes respiratory compromise ( ≥ grade 2 dyspnea)~* No history of CNS disease, including primary brain tumor, seizures, or carcinomatous meningitis~PATIENT CHARACTERISTICS:~* Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment~* Karnofsky performance status ≥ 60%~* Life expectancy \> 12 weeks~* Granulocyte count \> 1,500/mm\^3~* Platelet count \> 75,000/mm\^3~* Hemoglobin \> 8.0 g/dL~* Creatinine \< 1.5 times upper limit of normal (ULN)~* Bilirubin \< 1.5 times ULN~* SGOT/SGPT \< 1.5 times ULN~* Urinalysis ≤ 1+ proteinuria based on dipstick reading OR 2+ proteinuria on dipstick reading AND total urinary protein ≤ 3,500 mg on 24 hour urine collection and creatinine clearance ≥ 50 mL/min on a 24-hour urine collection~* No impairment of gastrointestinal (GI) function or GI disease that may affect or alter absorption of vatalanib (i.e., malabsorption syndromes)~* No myocardial infarction or significant change in anginal pattern within the last 6 months, symptomatic congestive heart failure (New York Heart Association class III or IV), or uncontrolled cardiac arrhythmia~* No pre-existing grade 3 or 4 clinical peripheral neuropathy~* No history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~* No deep vein thrombosis or pulmonary embolus within the past year~* No poorly controlled diabetes (fasting blood glucose \> 250) despite optimization of medical therapy~* No labile or poorly controlled hypertension (systolic blood pressure \> 160 mm Hg, diastolic blood pressure \> 90 mm Hg) despite maximal management with anti-hypertensives~* No serious uncontrolled, concurrent medical illness, including ongoing or active infection~  * Patients on Suppressive antibiotic therapy for chronic urinary tract infection are eligible~* No psychiatric illness or social situation that would limit compliance with treatment~* No currently active second malignancy other than nonmelanoma skin cancers~  * Not considered currently active if competed therapy and at \< 30% risk of relapse~* No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No grapefruit or grapefruit juice during study treatment~* No history of gastrectomy/small bowel resection~* At least 4 weeks since prior hormonal therapy, including ketoconazole, aminoglutethimide, systemic steroids (any dose), and megestrol acetate (any dose)~* At least 4 weeks since prior drug or herbal product known to decrease PSA levels (e.g., finasteride, saw palmetto, or PC-SPES)~* At least 4 weeks since prior major surgery and fully recovered~* At least 4 weeks since prior radiation therapy and fully recovered~* At least 8 weeks since the last dose of prior strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium~* Patients receiving bisphosphonate therapy prior to initiating protocol treatment must have received bisphosphonates for at least the past month~  * No bisphosphonate initiation for 1 month prior to and during study treatment~* No prior systemic chemotherapy for prostate cancer~* No prior antiangiogenic agents (thalidomide, bevacizumab)~* No other concurrent chemotherapy, investigational agents, radiotherapy (including palliative), or biologic therapy~* No biologic therapy or immunotherapy ≤ 4 weeks prior to study treatment~* No more than 1 prior therapy with an investigational agent, completed ≥ 4 weeks prior to study treatment~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No concurrent therapeutic warfarin or similar oral anticoagulant that is metabolized by the cytochrome p450 system~  * Heparin is allowed~* No other concurrent hormonal therapy except for the following:~  * Steroids for adrenal failure~ * Hormones for nondisease-related conditions (e.g., insulin for diabetes)~ * Intermittent dexamethasone

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues